enGene (ENGN) Expected to Announce Quarterly Earnings on Thursday

enGene (NASDAQ:ENGN) is expected to be announcing its Q4 2025 results before the market opens on Thursday, December 18th. Analysts expect the company to announce earnings of ($0.55) per share for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, December 26, 2025 at 4:00 PM ET.

enGene Trading Down 0.4%

Shares of NASDAQ ENGN opened at $8.43 on Tuesday. The firm has a market capitalization of $544.39 million, a PE ratio of -4.44 and a beta of -0.28. enGene has a one year low of $2.65 and a one year high of $11.14. The company has a current ratio of 10.34, a quick ratio of 10.34 and a debt-to-equity ratio of 0.09. The business has a 50-day moving average price of $7.86 and a two-hundred day moving average price of $5.64.

Hedge Funds Weigh In On enGene

Several institutional investors and hedge funds have recently added to or reduced their stakes in ENGN. Cresset Asset Management LLC acquired a new position in enGene in the second quarter valued at about $36,000. Paloma Partners Management Co acquired a new position in shares of enGene in the 2nd quarter worth approximately $38,000. Raymond James Financial Inc. grew its position in enGene by 383.6% during the 3rd quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock worth $68,000 after acquiring an additional 7,932 shares during the last quarter. Millennium Management LLC increased its holdings in enGene by 57.3% during the 3rd quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock valued at $140,000 after purchasing an additional 7,472 shares in the last quarter. Finally, Citadel Advisors LLC increased its holdings in enGene by 153.3% during the 3rd quarter. Citadel Advisors LLC now owns 58,370 shares of the company’s stock valued at $399,000 after purchasing an additional 35,327 shares in the last quarter. 64.16% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

ENGN has been the topic of several recent research reports. UBS Group raised their price objective on shares of enGene from $4.00 to $10.00 and gave the company a “neutral” rating in a research report on Wednesday, November 12th. Morgan Stanley raised their price target on shares of enGene from $18.00 to $19.00 and gave the company an “overweight” rating in a report on Wednesday, November 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of enGene in a research report on Tuesday, October 14th. Oppenheimer restated an “outperform” rating and set a $33.00 target price (up from $30.00) on shares of enGene in a report on Wednesday, November 12th. Finally, Raymond James Financial raised enGene from an “outperform” rating to a “strong-buy” rating and set a $27.00 price objective on the stock in a report on Tuesday, November 11th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $22.38.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.